Melanotan II is one of the more widely sold research peptides, and also one
where the safety record deserves as much attention as the pharmacology.
Chemical identity & structure.
Melanotan II is a synthetic cyclic peptide — a lactam-cyclized analog of
alpha-melanocyte-stimulating hormone (α-MSH), the body's natural pigmentation
signal. The cyclization makes it far more stable and potent than native α-MSH.
It is related to, but distinct from, PT-141 (bremelanotide), which was developed
from it.
Mechanism of action.
Melanotan II is a non-selective melanocortin-receptor agonist. It activates
MC1R — the receptor on melanocytes that drives melanin production, the basis for
its pigmentation effect — as well as MC4R and other melanocortin receptors. MC4R
activity is why it also affects appetite and sexual-arousal pathways. The
non-selectivity is central to both its effects and its side-effect profile.
Key research findings.
Research has documented increased melanin production (skin darkening) and
effects on sexual function. The literature also documents a meaningful
side-effect and safety picture: nausea and flushing are common, and there is
particular concern about effects on melanocytic lesions — moles darkening or
changing — which is a dermatological red flag because mole changes are also a
melanoma warning sign.
The research / citation base.
Melanotan II is not approved by the FDA or other major regulators. Health
agencies in multiple countries have issued public warnings against unregulated
melanotan products. Its evidence base is limited research plus a substantial
body of adverse-event reporting. This is a compound where the honest summary is:
real pharmacology, real and documented safety concerns, no regulatory approval.
Human clinical trial data.
Why this monograph does not give a non-trial dosing protocol — and that is deliberate. Melanotan II is not approved by any major regulator, and drug-safety agencies in several countries (including the UK's MHRA and Australia's TGA) have warned against unregulated melanotan products. The most serious documented concern is dermatological: MT-II is associated with darkening and change in melanocytic moles — and new, darkening, or changing moles are themselves warning signs for melanoma. Given the absence of any regulator-reviewed protocol, that specific safety signal, and a documented history of adulterated product sold outside any oversight, this monograph does not publish non-trial dose figures, which would imply a standardization and safety margin this compound does not have. In the double-blind, placebo-controlled crossover study by Wessells and colleagues (2000) in 10 men with erectile dysfunction and organic risk factors, Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection (PubMed).
Quality & sourcing notes.
A defined cyclic peptide should be confirmed on a batch-specific COA by mass
spectrometry and HPLC purity. A specific hazard: melanotan II and PT-141 are
different molecules that are sometimes confused or substituted — confirm which
compound a COA actually describes.
*Research-use note: Educational summary of published research. Melanotan II is
not an approved drug and carries documented safety concerns; this is research
context only and not medical advice.*
